Clinical Trial Update: Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for constitutive IL7R (C7R) modified banked allogeneic CD30.CAR EBVSTs in CD30-positive lymphomas, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma Alk-negative
• Anaplastic Large Cell Lymphoma Alk-positive
• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• CD30.CAR EBVSTs (CD30-targeted chimeric antigen receptor T cells with EBV-stimulated T cells and constitutive IL7R (C7R) modification)

Snippet

Sponsor: Baylor College of Medicine | Conditions: CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type | Phase 1 | Status: RECRUITING